Clinical trials: Still Disease
Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS)
Long Term Safety Study in Patients With HLH/MAS in Still's Disease Exposed to Gamifant.
This study aims to evaluate safety information in patients with HLH/MAS in Still's disease exposed to Gamifant.
- Conditions
- Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS), Still Disease
- Trial name
- NCT07909005
- Testing
- Local laboratory testing, Local Lab Tests
- Where
- 18 sites in United States
- Volunteers
- 70 people
- Sponsor
- Swedish Orphan Biovitrum
Condition 1. Children With ALL Are Still Alive and the Age of 18 Years of Age., Condition 2. Has Been Completed to Guide the Treatment Regimen Were in Remission.
The Related Factors With Resilience in Caregivers Whose Child With Leukemia
The purpose of this study was to explore caregivers stress, family functioning, social support and family resilience of families whose children had acute lymphoblastic leukemia.
- Conditions
- Condition 1. Children With ALL Are Still Alive and the Age of 18 Years of Age., Condition 2. Has Been Completed to Guide the Treatment Regimen Were in Remission., Condition 3. Caregiver Can or Taiwanese Language Communicator.
- Trial name
- NCT01249781
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- China Medical University Hospital
Crohn Disease, Ulcerative Colitis
Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases
A Clinical Study on the Safety and Effectiveness of Targeting CD7 Chimeric Antigen Receptor T Cells in the Treatment of Autoimmune Diseases
- Conditions
- Crohn Disease, Ulcerative Colitis, Dermatomyositis, Still Disease
- Trial name
- NCT05239702
- Testing
- CD7 CAR T-cells
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Zhejiang University
Anemia, Low Birth Weight
Dietary Diversity is Associated With Maternal Anemia and Key Prenatal Outcomes in Ethiopia
Background: Maternal and child under-nutrition is the underlying cause of death for millions across the globe. Anemia during pregnancy is among the leading nutritional disorders with serious short and long term consequences to…
- Conditions
- Anemia, Low Birth Weight, Pre-Term Birth, Still Birth
- Trial name
- NCT02620943
- Where
- Ethiopia
- Volunteers
- 374 people
- Sponsor
- Dilla University
Juvenile Idiopathic Arthritis
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
Juvenile Idiopathic Arthritis (JIA) is the most common type of arthritis that affects children. The term "idiopathic" means "of unknown origin".
- Trial name
- SELECT-sJIA (NCT05609630)
- Testing
- Upadacitinib, Tocilizumab
- Where
- 45 sites in United States, Argentina and 15 more
- Volunteers
- 90 people
- Sponsor
- AbbVie
Systemic Juvenile Idiopathic Arthritis With Active Flare
Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
This two-part study assessed the sustained efficacy of canakinumab in the double-blind Part II and the ability to taper steroids in the open label Part I.
- Trial name
- β-SPECIFIC 2 (NCT00889863)
- Testing
- canakinumab
- Where
- 73 sites in United States, Argentina and 17 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Active Systemic, Onset Juvenile Idiopathic Arthritis
Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic Arthritis
This study has the following objectives: Primary objective: To determine the safety and tolerability of oral ITF2357 in patients with active SOJIA with inadequate response or intolerance to standard therapy with oral steroids and…
- Trial name
- SOJIA (NCT00570661)
- Testing
- ITF2357
- Where
- 5 sites in Romania, Serbia
- Volunteers
- 17 people
- Sponsor
- Italfarmaco
Systemic Juvenile Idiopathic Arthritis
Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)
This study assessed the initial efficacy and safety of canakinumab over a 4 week period in patients with systemic juvenile idiopathic arthritis (SJIA) having a flare.
- Trial name
- β-SPECIFIC 1 (NCT00886769)
- Testing
- Canakinumab
- Where
- 91 sites in United States, Argentina and 20 more
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Juvenile Idiopathic Arthritis
Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
This is a double-blind, Phase III study to evaluate the efficacy, safety and PK of MRA in patients with sJIA.
- Trial name
- NCT00144599
- Testing
- MRA(Tocilizumab)
- Volunteers
- 56 people
- Sponsor
- Chugai Pharmaceutical
Systemic Juvenile Idiopathic Arthritis
Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
An open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with sJIA who were participated in Studies MRA011JP or MRA316JP
- Trial name
- NCT00144612
- Testing
- MRA(Tocilizumab)
- Volunteers
- 60 people
- Sponsor
- Chugai Pharmaceutical
Systemic-Onset Juvenile Idiopathic Arthritis
Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS
1. Main objective: To test the efficacy of anakinra treatment in children or young adults with corticosteroid-resistant or -dependent Systemic-Onset Juvenile Idiopathic Arthritis (SO-JIA) 2.
- Trial name
- NCT00339157
- Testing
- Anakinra, Pneumo23
- Where
- 6 sites in France
- Volunteers
- 24 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France